
News
Stay up to date. The MLL Munich Leukemia Laboratory stands for innovation and the best leukemia diagnostics. Here you will find the latest research and study results related to hematological diagnostics and the therapy based on them, as well as other exciting news and events.
The magazine
Anja Neumayer
at 19.04.2022
The contact point for all departments – the MLL Secretariat – introduces itself
Every day, the MLL team works together to provide patients worldwide with the best possible therapy through rapid and targeted leukemia diagnostics. But what exactly does the day-to-day work of the more than 200 employees look like? What departments and areas are there? Our magazine series, “MLL introduces itself”, provides you with an insight into our laboratory, with the third section introducing you to our secretariat.
Dr. rer. nat. Manja Meggendorfer, MBA
at 19.04.2022
Our new website has arrived
Over the last two years we have worked hard on our brand architecture, developing it further, and making it fit for the future. During the course of this we have harmonized the layout of our websites and improved them by incorporating your feedback as a site user. The websites of MLL, MLL MVZ, and MLLSEQ are now available in a new and harmonized design. The goal was to increase the user-friendliness of the website and to allow for rapid and targeted navigation through its pages. We look forward to your visit and to your feedback!
at 21.03.2022
Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program
The MLL Munich Leukemia Laboratory has a new collaboration partner: Following the launch of the xGen™ NGS portfolio from global genomics solutions provider Integrated DNA Technologies, MLL has joined the Align program. As the first European partner in the program, MLL and IDT aim to jointly advance genomics research. Read all about the new collaboration in MLL Magazine.
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 20.12.2021
We Want to Say Thank You: The MLL Annual Review for 2021
Dr. rer. nat. Christine Käppel
at 18.12.2021
MLL Dx Successfully Accredited by the College of American Pathologists (CAP)
PD Dr. med. Gregor Hörmann, PhD
at 16.10.2021
Good Findings Start with Preanalytics – Our Sample Receipt Introduces Itself
Dr. rer. nat. Sandra Weißmann
at 19.04.2022
Validation of the laboratory-specific conversion factor for BCR::ABL1 p210
The standardization of BCR::ABL1 quantification according to the international scale (IS) is of great importance for managing chronic myeloid leukemia (CML). The laboratory-specific conversion factor required for this is redetermined annually during quality assurance rounds. Over the last five years, MLL has been a member of the EUTOS project, in which, among other things, a procedure was developed to allow each and every laboratory to determine its own conversion factor in the future. We have collected the most important results of the project for you plus its associated future innovations.
Dr. rer. nat. Isolde Summerer
at 22.02.2022
CHIP highly relevant to individual risk profile for individuals aged ≥80 years
Clonal genetic changes in hematopoietic cells occur with increasing frequency with advancing age, even in individuals without hematological neoplasia. Due to the growing number of individuals aged ≥80 years in our society, the need arises to investigate the clinical relevance of such clonal hematopoiesis of indeterminate potential (CHIP). A recently published study by Rossi and colleagues (Blood 2021;138 (21): 2093–2105) examined blood samples from 1794 individuals aged ≥80 years who have not been diagnosed with hematological neoplasia for mutations in 47 genes implicated in myeloid neoplasia
Dr. rer. nat. Ines Schmidts
at 20.12.2021
63rd ASH Annual Meeting & Exposition – a Postscript
Dr. rer. nat. Manja Meggendorfer, MBA
at 20.12.2021
Hematological Whole Genome and Transcriptome Sequencing as a New Diagnostic Tool for Acute Leukemias
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 14.10.2021
A Difficult Case: What the Diagnostics of Tomorrow Will Look Like
Dr. rer. nat. Anna Stengel
at 18.08.2021
CLL: The more complex the karyotype, the less favorable the prognosis
In addition to TP53 alterations and IGHV mutation status, a complex karyotype is also considered a genetic risk factor of chronic lymphocytic leukemia (CLL). However, the cytogenetics/chromosome analysis required to detect a complex karyotype has often not been an integral part of CLL diagnostics to date. New data now show that as the number of cytogenetically detected chromosomal alterations increases, survival of treated CLL patients decreases. These results are summarized here.
Dr. rer. nat. Constanze Kühn
at 16.08.2021
MTLAs, doctors and artificial intelligence at MLL – a good team!
Dr. med. Christian Pohlkamp
at 06.08.2021
MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 30.09.2020
BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology
Dr. rer. nat. Ines Schmidts
at 18.02.2020
The Use of Artificial Intelligence at MLL Munich Leukemia Laboratory
Niroshan Nadarajah
at 18.11.2019
MLLi:ir - A diagnostic interpretation report for NGS data
Dr. Wencke Walter
at 15.03.2022
Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing
In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.
Dr. Wencke Walter
at 28.12.2021
Research Report 2021
Dr. Wencke Walter
at 10.02.2020
Genomic & Transcriptomic Data Visualization
Dr. Wencke Walter
at 04.12.2019
Analysis of pharmacogenomic variants by WGS data for AML patients with altered response to treatment
Dr. Wencke Walter
at 02.12.2019
AML and MDS – the ever-expanding potential of genetics to define clinically relevant subclasses
Dr. Wencke Walter
at 18.08.2019
Large-scale sequencing experience from the MLL 5K project
Currently there are no upcoming events.
You may also be interested in
Your contact person

»Transparent communication both internally and externally is important to us.«
Sarah Gallinger